WO2001057084A1

WO2001057084A1 - Crystallisation of a glp-1 analogue

Info

Publication number: WO2001057084A1
Application number: PCT/DK2001/000067
Authority: WO
Inventors: Anne Charlotte Arentsen
Original assignee: Novo Nordisk A/S
Priority date: 2000-01-31
Filing date: 2001-01-31
Publication date: 2001-08-09
Also published as: AU2001228327A1

Abstract

A process for producing crystals of a GLP-1 analogue by preparing an aqueous solution comprising a GLP-1 analogue, a salt, and an organic solvent, and by isolating of the crystals after formation.

Description

Crystallisation of a GLP-1 analogue

The present invention relates to novel crystals of GLP-1 and analogues thereof, such as needle shaped crystals, and processes for the preparation of crystals of GLP-1 and analogues thereof.

Background

The hormones regulating insulin secretion belong to the so-called enteroinsular axis, designating a group of hormones, released from the gastrointestinal mucosa in response to the presence and absorption of nutrients in the gut, which promote an early and potentiated release of insulin. The enhancing effect on insulin secretion, the so-called incretin effect, is probably essential for a normal glucose tolerance. Many of the gastrointestinal hormones, including gastrin and secretin (cholecystokinin is not insulinotropic in man), are insulinotropic, but the only physiologically important ones, those that are responsible for the incretin effect, are the glucose-dependent insulinotropic polypeptide, GIP, and glucagon-like peptide-1 (GLP-1). Because of its insulinotropic effect, GIP, isolated in 1973 (1) immediately attracted considerable interest among diabetologists. However, numerous investigations carried out during the following years clearly indicated that a defective secretion of GIP was not involved in the pathogenesis of insulin-dependent diabetes mellitus (IDDM) or non-insulin- dependent diabetes mellitus (NIDDM) (2). Furthermore, as an insulinotropic hormone, GIP was found to be almost ineffective in NIDDM (2). The other incretin hormone, GLP-1 is the most potent insulinotropic substance known (3). Unlike GIP, it is surprisingly effective in stimulating insulin secretion in NIDDM patients. In addition, and in contrast to the other insulinotropic hormones (perhaps with the exception of secretin) it also potently inhibits glucagon secretion. Because of these actions it has pronounced blood glucose lowering effects par- ticularly in patients with NIDDM.

Description of the invention

Human GLP-1 is a 37 amino acid residue peptide originating from preproglucagon which is synthesised i.a. in the L-cells in the distal ileum, in the pancreas and in the brain. Processing of preproglucagon to give GLP-1 (7-36)amide, GLP-1 (7-37) and GLP-2 occurs mainly in the L-cells. A simple system is used to describe fragments and analogues of this peptide. Thus, for example, Gly⁸-GLP-1 (7-37) designates a fragment of GLP-1 formally derived from GLP-1 by deleting the amino acid residues Nos. 1 to 6 and substituting the naturally occurring amino acid residue in position 8 (Ala) by Gly. Similarly, Lys³⁴(N^ε- tetradecanoyl)-GLP-1 (7-37) designates GLP-1 (7-37) wherein the ε-amino group of the Lys residue in position 34 has been tetradecanoylated. GLP-1 and analogues thereof can be produced by a method which comprises culturing or fermenting a host cell containing a DNA sequence encoding the GLP-1 analogue and capable of expressing said analogue in a suitable nutrient medium under conditions permitting the expression of the peptide, after which the resulting GLP-1 analogue is recovered from the cul- ture or fermentation broth.

The implementation of a crystallisation step in the manufacturing process for the preparation of a GLP-1 analogue resulted in removal of coloured compounds (coloured impurities) from the fermentation broth, reduction of yeast host cell proteins, such as Saccharo- myces cerevisiae proteins (SCP) as well as removal of water, and low loss of the GLP-1 ana- log from the mother liquor.

The GLP-1 analog was then re-dissolved and further purified by conventional High Performance Cation Exchange Chromatography (HP-CIEC) and Reverse Phase High Performance Liquid Chromatography (RP-HPLC) followed by a second crystallisation step at the pi of the GLP-1 analogue. Hereafter, the analogue was acylated, e.g. as disclosed in WO 98/08871 , and the resulting solution containing mono-acylated GLP-1 analogue was further purified by conventional RP-HPLC and finally precipitated at pi of the mono-acylated GLP-1 analogue.

Thus, the resulting crystals are an important and useful intermediate product in the manufacturing process for preparing a GLP-1 analogue and for preparing a mono-acylated GLP-1 analogue. The resulting crystals of the GLP-1 analogue are also useful in the preparation of a pharmaceutical composition, such as an injectable drug, comprising the crystals and a pharmaceutically acceptable carrier.

Accordingly, the present invention relates to a process for producing crystals of a GLP-1 analogue comprising: a) preparing an aqueous solution comprising a GLP-1 analogue, a salt, and an organic solvent, and b) isolating the crystals after formation.

The GLP-1 analogue to be crystallized in step a) is either substantially pure or is impure. The purity can be measured by analytical HPLC and/or capillary electrophoresis. In step a) a buffer may optionally be added to said solution. Usually it is most convenient to add a buffer to the solution, such as any buffer including but not limited to: citrate buffers, phosphate buffers, tris buffers, bis-Tris buffer, borate buffers, lactate buffers, glycyl gly- cin buffers, arginine buffers, carbonate buffers, acetate buffers, glutamate buffers, ammonium buffers, glycin buffers, alkylamine buffers, aminoethyl alcohol buffers, ethylenediamine buffers, tri-ethanol amine, imidazole buffers, pyridine buffers and barbiturate buffers and mixtures thereof. The concentration of buffer added is easily decided by the skilled practitioner using his common general knowledge, but will usually be in the range from 0 mM to 100 mM, such as 0.5 mM to 50 mM, e.g. 5-10 mM.

Further in step a) pH of the solution may be adjusted by means of an acid or base to keep it constant or it may vary, provided that pi of the GLP-1 analogue is not reached. Usu- ally it is most convenient to adjust pH with an acid, e.g. HCI, if pH of the aqueous solution is above the isoelectric point (hereinafter pi) of the GLP-1 analogue, or with a base, e.g. NaOH, if pH of the aqueous solution is below the pi of the GLP-1 analogue. The pH of the solution is easily decided by the skilled practitioner using his common general knowledge, but will usually be within a certain range from the pi of the GLP-1 analogue, such as between about pl-4 (id est, pi minus 4) and pi or between about pi and pl+4 (id est pi plus 4), depending on whether the aqueous solution of the GLP-1 analogue is below the pi or above the pi. The pH of the aqueous solution may be adjusted relatively far from the pi of the GLP-1 analogue, such as at about pl-4 or pl+4 and then, optionally, by step or linear gradient, be driven towards the pi until formation of crystals occur, in particular needle shaped crystals. In case of the GLP-1 analogue being Arg³ GLP-1(7-37), having a pi of about 5.4, it is preferred to prepare an aqueous solution of Arg³⁴GLP-1 (7-37) above pi, preferably at about pH 8.5-9.5, and then adjust the pH to about pH 6-7 with an acid, e.g. HCI. In one embodiment of the invention the pH is adjusted so that pl-4<pH<pl, preferably pl-2<pH<pl. In another embodiment of the invention the pH is adjusted so that pl<pH<pl+4, preferably pl<pH<pl+2. Further in step a) an excipient may optionally be added that influence the stability or solubility of the GLP-1 analogue.

In one embodiment of the invention the crystals are needle shaped crystals of a GLP-1 analogue having a length of at least 0.5μm. In another embodiment of the invention the crystals are needle shaped crystals of a GLP-1 analogue having a length of at least 2μm. In a further embodiment of the invention the crystals are needle shaped crystals of a GLP-1 analogue having a length of at least 8μm. In a further embodiment of the invention the crystals are needle shaped crystals of a GLP-1 analogue having a length of 0.5μm to 50μm, such as 2μm to 50μm, e.g. 2μm to 30μm. In a further embodiment of the invention the crystals are needle shaped crystals of a GLP-1 analogue having a length of 8μm to 50μm. In another embodiment of the invention the GLP-1 analogue to be crystallized has a purity of less than 98%, as measured by HPLC. In a further embodiment of the invention the GLP-1 analogue to be crystallized has a purity of less than 95%, such as less than 90%, as measured by HPLC.

In another embodiment of the invention the GLP-1 analogue to be crystallized has a purity of more than 20%, such as more than 30%, as measured by HPLC. In a further em- bodiment of the invention the GLP-1 analogue to be crystallized has a purity between 20% and 90%, such as a purity between 20% and 50%, as measured by HPLC.

In a further embodiment of the invention the GLP-1 analogue in the aqueous solution is present in a concentration of at least 0.5 mg/ml. In a further embodiment of the invention the GLP-1 analogue in the aqueous solution is present in a concentration of from 0.5 mg/ml to 20 mg/ml, such as 2-10 mg/ml.

In a further embodiment of the invention the GLP-1 analogue is selected from non- synthetic GLP-1 analogues.

In a further embodiment of the invention the GLP-1 analogue is selected from the Thr⁸, Met⁸, Gly⁸ and Val⁸ analogues of GLP-1 (7-37) and GLP-1 (7-36) amide, more preferred the Gly⁸ and Val⁸ analogues of GLP-1 (7-37) and GLP-1 (7-36) amide, most preferred the Val⁸ analogues of GLP-1 (7-37) and GLP-1 (7-36) amide.

In a further embodiment of the invention the GLP-1 analogue has the formula II: 7 8 9 10 11 12 13 14 15 16 17 His-Xaa-Xaa-Gly-Xaa-Phe-Thr-Xaa-Asp-Xaa-Xaa-

18 19 20 21 22 23 24 25 26 27 28 Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Phe-

29 30 31 32 33 34 35 36 37 38 lle-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa

39 40 41 42 43 44 45 Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa (II) wherein

Xaa at position 8 is Ala, Gly, Ser, Thr, Leu, lie, Val, Glu, Asp, Met, or Lys,

Xaa at position 9 is Glu, Asp, or Lys,

Xaa at position 11 is Thr, Ala, Gly, Ser, Leu, lie, Val, Glu, Asp, or Lys, Xaa at position 14 is Ser, Ala, Gly, Thr, Leu, lie, Val, Glu, Asp, or Lys,

Xaa at position 16 is Val, Ala, Gly, Ser, Thr, Leu, lie, Tyr, Glu, Asp, or Lys,

Xaa at position 17 is Ser, Ala, Gly, Thr, Leu, lie, Val, Glu, Asp, or Lys,

Xaa at position 18 is Ser, Ala, Gly, Thr, Leu, lie, Val, Glu, Asp, or Lys,

Xaa at position 19 is Tyr, Phe, Trp, Glu, Asp, or Lys, Xaa at position 20 is Leu, Ala, Gly, Ser, Thr, Leu, He, Val, Glu, Asp, or Lys,

Xaa at position 21 is Glu, Asp, or Lys, Xaa at position 22 s Gly, Ala, Ser, Thr, Leu, lie, Val, Glu, Asp, or Lys, Xaa at position 23 s Gin, Asn, Arg, Glu, Asp, or Lys, Xaa at position 24 s Ala, Gly, Ser, Thr, Leu, lie, Val, Arg, Glu, Asp, or Lys, Xaa at position 25 s Ala, Gly, Ser, Thr, Leu, lie, Val, Glu, Asp, or Lys, Xaa at position 26 s Lys, Arg, Gin, Glu, Asp, or His, Xaa at position 27 s Glu, Asp, or Lys, Xaa at position 30 s Ala, Gly, Ser, Thr, Leu, lie, Val, Glu, Asp, or Lys, Xaa at position 31 s Trp, Phe, Tyr, Glu, Asp, or Lys, Xaa at position 32 s Leu, Gly, Ala, Ser, Thr, lie, Val, Glu, Asp, or Lys, Xaa at position 33 s Val, Gly, Ala, Ser, Thr, Leu, lie, Glu, Asp, or Lys, Xaa at position 34 s Lys, Arg, Glu, Asp, or His, Xaa at position 35 s Gly, Ala, Ser, Thr, Leu, lie, Val, Glu, Asp, or Lys, Xaa at position 36 s Arg, Lys, Glu, Asp, or His, Xaa at position 37 s Gly, Ala, Ser, Thr, Leu, lie, Val, Glu, Asp, or Lys, or is deleted, Xaa at position 38 s Arg, Lys, Glu, Asp, or His, or is deleted, Xaa at position 39 s Arg, Lys, Glu, Asp, or His, or is deleted, Xaa at position 40 s Asp, Glu, or Lys, or is deleted, Xaa at position 41 s Phe, Trp, Tyr, Glu, Asp, or Lys, or is deleted, Xaa at position 42 s Pro, Lys, Glu, or Asp, or is deleted, Xaa at position 43 s Glu, Asp, or Lys, or is deleted, Xaa at position 44 s Glu, Asp, or Lys, or is deleted, and Xaa at position 45 is Val, Glu, Asp, or Lys, or is deleted, or (a) a C-1 -6-ester thereof, (b) amide, C-1 -6-alkylamide, or C-1 -6-dialkylamide thereof and/or (c) a pharmaceutically acceptable salt thereof, provided that

(i) when the amino acid at position 37, 38, 39, 40, 41 , 42, 43 or 44 is deleted, then each amino acid downstream of the amino acid is also deleted. In a further embodiment of the GLP-1 analogue of formula II, the amino acids at positions 37-45 are absent. In another embodiment of the GLP-1 analogue of formula II, the amino acids at positions 38-45 are absent.

In another embodiment of the GLP-1 analogue of formula II, the amino acids at positions 39-45 are absent.

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 8 is Ala, Gly, Ser, Thr, Met, or Val. In another embodiment of the GLP-1 analogue of formula II, Xaa at position 8 is Gly, Thr, Met, or Val.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 8 is Val.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 9 is Glu. In another embodiment of the GLP-1 analogue of formula , Xaa at position 11 is Thr.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 14 is Ser.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 16 is Val.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 17 is Ser.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 18 is Ser, Lys, Glu, or Asp.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 19 is Tyr, Lys, Glu, or Asp.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 20 is Leu, Lys, Glu, or Asp. In another embodiment of the GLP-1 analogue of formula , Xaa at position 21 is Glu,

Lys, or Asp.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 22 is Gly, Glu, Asp, or Lys.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 23 is Gin, Glu, Asp, or Lys.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 24 is Ala, Glu, Asp, or Lys.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 25 is Ala, Glu, Asp, or Lys. In another embodiment of the GLP-1 analogue of formula , Xaa at position 26 is Lys,

Glu, Asp, or Arg.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 27 is Glu, Asp, or Lys.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 30 is Ala, Glu, Asp, or Lys.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 31 is Trp, Glu, Asp, or Lys.

In another embodiment of the GLP-1 analogue of formula , Xaa at position 32 is Leu, Glu, Asp, or Lys. In another embodiment of the GLP-1 analogue of formula , Xaa at position 33 is Val,

Glu, Asp, or Lys. In another embodiment of the GLP-1 analogue of formula II, Xaa at position 34 is Lys, Arg, Glu, or Asp.

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 35 is Gly, Glu, Asp, or Lys. In another embodiment of the GLP-1 analogue of formula II, Xaa at position 36 is Arg,

Lys, Glu, or Asp.

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 37 is Gly, Glu, Asp, or Lys.

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 38 is Arg, or Lys, or is deleted.

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 39 is deleted.

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 40 is deleted. In another embodiment of the GLP-1 analogue of formula II, Xaa at position 41 is deleted.

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 42 is deleted.

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 43 is de- leted.

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 44 is deleted.

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 45 is deleted. In another embodiment of the GLP-1 analogue of formula II, Xaa at position 26 is Arg, each of Xaa at positions 37-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-36).

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 26 is Arg, each of Xaa at positions 38-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-37).

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 26 is Arg, each of Xaa at positions 39-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-38).

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 34 is Arg, each of Xaa at positions 37-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-36). In another embodiment of the GLP-1 analogue of formula II, Xaa at position 34 is Arg, each of Xaa at positions 38-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-37).

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 34 is Arg, each of Xaa at positions 39-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-38).

In another embodiment of the GLP-1 analogue of formula II, Xaa at positions 26 and 34 is Arg, Xaa at position 36 is Lys, each of Xaa at positions 37-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-36). In another embodiment of the GLP-1 analogue of formula II, Xaa at positions 26 and

34 is Arg, Xaa at position 36 is Lys, each of Xaa at positions 38-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-37).

In another embodiment of the GLP-1 analogue of formula II, Xaa at positions 26 and 34 is Arg, Xaa at position 36 is Lys, each of Xaa at positions 39-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-38).

In another embodiment of the GLP-1 analogue of formula II, Xaa at positions 26 and 34 is Arg, Xaa at position 38 is Lys, each of Xaa at positions 39-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-38).

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 8 is Thr, Ser, Gly, or Val, Xaa at position 37 is Glu, Xaa at position 36 is Lys, each of Xaa at positions 38- 45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-37).

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 8 is Thr, Ser, Gly, or Val, Xaa at position 37 is Glu, Xaa at position 36 is Lys, each of Xaa at positions 39- 45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-38). In another embodiment of the GLP-1 analogue of formula II, Xaa at position 8 is Thr,

Ser, Gly or Val, Xaa at position 37 is Glu, Xaa at position 38 is Lys, each of Xaa at positions 39- 45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-38).

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 18, 23 or 27 is Lys, and Xaa at positions 26 and 34 is Arg, each of Xaa at positions 37-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-36).

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 18, 23 or 27 is Lys, and Xaa at positions 26 and 34 is Arg, each of Xaa at positions 38-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-37).

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 18, 23 or 27 is Lys, and Xaa at positions 26 and 34 is Arg, each of Xaa at positions 39-45 is deleted, and each of the other Xaa is the amino acid in native GLP-1 (7-38). In another embodiment of the GLP-1 analogue of formula II, Xaa at position 8 is Thr,

Ser, Gly, or Val, Xaa at position 18, 23 or 27 is Lys, and Xaa at position 26 and 34 is Arg, each of Xaa at positions 37-45 is deleted, and each of the other Xaa is the amino acid in native GLP-

1(7-36). In another embodiment of the GLP-1 analogue of formula II, Xaa at position 8 is Thr,

Ser, Gly, or Val, Xaa at position 18, 23 or 27 is Lys, and Xaa at position 26 and 34 is Arg, each of Xaa at positions 38-45 is deleted, and each of the other Xaa is the amino acid in native GLP-

1(7-37).

In another embodiment of the GLP-1 analogue of formula II, Xaa at position 8 is Thr, Ser, Gly, or Val, Xaa at position 18, 23 or 27 is Lys, and Xaa at position 26 and 34 is Arg, each of Xaa at positions 39-45 is deleted, and each of the other Xaa is the amino acid in native GLP-

1(7-38).

Such GLP-1 analogues of formula II includes, but is not limited to, Arg²⁶-GLP-1 (7-37);

Arg³ -GLP-1(7-37); Lys³⁶-GLP-1(7-37); Arg²⁶³⁴Lys³⁶-GLP-1 (7-37); Arg²⁶³⁴Lys³⁸GLP-1(7-38); Arg²⁶³⁴Lys³⁹-GLP-1 (7-39); Arg∞^Lys^-GLP-l (7-40); Arg²⁶Lys³⁶-GLP-1 (7-37); Arg³⁴Lys^3β-GLP-

1(7-37); Arg²⁶Lys³⁹-GLP-1 (7-39); Arg³⁴Lys⁴⁰-GLP-1(7-40); Arg²⁶³⁴Lys³⁶'³⁹-GLP- 1(7-39);

Arg²⁶³ Lys³⁶'⁴⁰-GLP-1(7-40); Gly⁸Arg26-GLP-1(7-37); Gly⁸Arg³⁴-GLP-1 (7-37); Val⁸-GLP-1 (7-37);

Thr⁸-GLP-1 (7-37); Gly⁸-GLP- 1(7-37); Met⁸-GLP-1(7-37); Gly⁸Lys³⁶-GLP-1(7-37);

GlyΑrg^Lys∞-GLP-l (7-37); Gly⁸Arg²⁶³⁴Lys³⁹-GLP-1 (7-39); Gl/Arg^Lys^-GLP-l (7-40); Gly⁸Arg²⁶Lys³⁶-GLP-1 (7-37); Gly'Αrg^Lys^-GLP-l (7-37); Gly⁸Arg²⁶Lys³⁹-GLP-1 (7-39);

Gly⁸Arg³⁴Lys⁴⁰-GLP-1 (7-40); Gly⁸Arg²⁶'³⁴Lys^36|39-GLP-1 (7-39); Gly⁸Arg²⁶'³⁴Lys³⁶' ⁰-GLP-1 (7-40);

Arg²⁶³⁴Lys³⁸GLP-1 (7-38); Arg²⁶³⁴Lys³⁹GLP-1 (7-39); Arg²⁶³ Lys⁴⁰GLP-1 (7-40);

Arg²⁶³⁴Lys⁴¹GLP-1 (7-41); Arg²⁶'³⁴Lys⁴²GLP-1(7-42); Arg ⁶³⁴Lys⁴³GLP-1(7-43); Arg²⁶³⁴Lys⁴⁴GLP-

1(7-44); Arg²⁶'³⁴Lys ⁵GLP-1(7-45); Arg²⁶³⁴Lys³⁸GLP-1(1-38); Arg²⁶³ Lys³⁹GLP-1(1-39); Arg²⁶'³⁴Lys⁴⁰GLP-1(1-40); Arg²⁶³⁴Lys⁴¹GLP-1(1-41); Arg²⁶³⁴Lys⁴²GLP-1(1-42); Arg²⁶³⁴Lys⁴³GLP-

1(1-43); Arg^Lys^GLP-IO^); Arg²⁶³⁴Lys⁴⁵GLP-1(1-45); Arg²⁶³ Lys³⁸GLP-1(2-38);

Arg²⁶³⁴Lys³⁹GLP-1 (2-39); Arg²⁶'³ Lys ⁰GLP-1(2-40); Arg²⁶³⁴Lys⁴¹GLP-1 (2-41); Arg²⁶³⁴Lys⁴²GLP-

1(2-42); Arg^{26 ;i} Lys ³GLP-1(2-43); Arg ⁶'³⁴Lys⁴⁴GLP-1(2-44); Arg²⁶³⁴Lys⁴⁵GLP-1(2-45);

Arg²⁶³⁴Lys³⁸GLP-1 (3-38); Arg²⁶³⁴Lys³⁹GLP-1 (3-39); Arg²⁶³⁴Lys⁴⁰GLP-1(3-40); Arg²⁶³⁴Lys⁴¹GLP- 1 (3-41 ); Arg²⁶³⁴Lys⁴²GLP-1 (3-42); Arg²⁶³⁴Lys ³GLP-1 (3-43); Arg^Lys^GLP-l (3-44);

Arg²⁶'³ Lys ⁵GLP-1(3-45); Arg²⁶³ Lys³⁸GLP-1 (4-38); Arg²⁶³⁴Lys³⁹GLP-1(4-39); Arg^^Lys^GLP-

1(4-40); Arg²⁶³ Lys⁴¹GLP-1(4-41); Arg²⁶³⁴Lys⁴²GLP-1(4-42); Arg²⁶³ Lys⁴³GLP-1 (4-43);

Arg²⁶³⁴Lys GLP-1(4-44); Arg²⁶³⁴Lys⁴⁵GLP-1 (4-45); Arg²⁶³⁴Lys³⁸GLP-1 (5-38); Arg²⁶³⁴Lys³⁹GLP-

1(5-39); Arg²⁶'³⁴Lys⁴⁰GLP-1 (5-40); Arg ⁶³⁴Lys ¹GLP-1(5-41); Arg²⁶³⁴Lys ²GLP-1(5-42); Arg²⁶³⁴Lys⁴³GLP-1 (5-43); Arg²⁶³⁴Lys⁴⁴GLP-1 (5-44); Arg²⁶³⁴Lys⁴⁵GLP-1 (5-45); Arg²⁶³⁴Lys³⁸GLP-

1(6-38); Arg²⁶³ Lys³⁹GLP-1(6-39); Arg^^Lys^GLP-^e^O); Arg²⁶³⁴Lys⁴¹GLP-1(6-41); Arg²⁶³ Lys⁴²GLP-1 (6-42); Arg²⁶³⁴Lys⁴³GLP-1(6-43); Arg∞^Lys^GLP-lβ-M); Arg²⁶³⁴Lys ⁵GLP- 1(6-45); Arg²⁶Lys³⁸GLP-1 (1-38);

Arg²⁶³⁴Lys³⁶'³⁸GLP-1(1-38); Arg²⁶Lys³⁸GLP-1 (7-38); Arg³⁴Lys³⁸GLP-1(7-38); Arg ⁶'³⁴Lys³⁶³⁸GLP-1(7-38); Arg²⁶³⁴Lys³⁸GLP- 1(7-38); Arg²⁶Lys³⁹GLP-1(1-39); Arg³⁴Lys³⁹GLP-1(1-39); Arg²⁶³⁴Lys³⁶³⁹GLP-1(1-39); Arg²⁶Lys³⁹GLP-1(7-39); Arg³⁴Lys³⁹GLP-1(7-39) and Arg²⁶³ Lys³⁶'³⁹GLP-1(7-39). Each one of these specific GLP-1 analogues constitutes an alternative embodiment of the invention. In a further embodiment of the invention the GLP-1 analogue has the formula III

A-HN-GLP-1(8-B)-X (III) wherein

wherein R¹, R² and R³ are independently H, lower alkyl having 1 to 6 carbon atoms, optionally substituted phenyl, NH₂, NH-CO-(lower alkyl), -OH, lower alkoxy having 1 to 6 carbon atoms, halogen, SO₂-(lower alkyl) or CF₃, said phenyl is optionally substituted with at least one group selected from NH₂, -OH, lower alkyl or lower alkoxy having 1-6 carbon atoms, halogen, SO - (lower alkyl), NH-CO-(lower alkyl) or CF₃, or R¹ and R² may together form a bond; Y is a five or six membered ring system selected from the group consisting of:

wherein Z is N, O or S, said ring system is optionally substituted with one or more functional groups selected from the group consisting of NH₂, NO₂, OH, C^ alkyl, d-β alkoxy, halogen (Cl, Br, F, I), CF₃ and aryl;

B is an integer in the range of 35-45; and

X is -OH, -NH₂, or a Ci-e alkyl amide or Ci-s dialkyl amide group; or an analogue thereof.

Such GLP-1 analogues of formula III includes, but is not limited to Arg²⁶-GLP-1 (7-37); Arg^-GLP-I (7-37); Lys³⁶-GLP-1 (7-37);

Arg²⁶³⁴Lys³⁶-GLP-1 (7-37); Arg²⁶³⁴Lys³⁸GLP-1 (7-38);

Arg^{26 :!4}Lys³⁹-GLP-1 (7-39); Arg^Lys^-GLP-l (7-40);

Arg²⁶Lys³⁶-GLP-1 (7-37); Arg^Lys -GLP-l (7-37);

Arg²⁶Lys³⁹-GLP-1 (7-39); Arg^Lys^-GLP-l (7-40); Arg ^Lys∞^-GLP-l (7-39); Arg ^Lys^-GLP-l (7-40);

Gly⁸Arg²⁶-GLP-1 (7-37); Gly'Αrg^-GLP-l (7-37);

Gly⁸Lys³⁶-GLP-1 (7-37); Gly⁸Arg²⁶³⁴Lys³⁶-GLP-1 (7-37);

Gly⁸Arg²⁶³⁴Lys³⁹-GLP-1 (7-39); Gly⁸Arg²⁶³⁴Lys ⁰-GLP-1 (7-40);

Gly⁸Arg²⁶Lys³⁶-GLP-1 (7-37); Gly⁸Arg³⁴Lys³⁶-GLP-1 (7-37); Gly⁸Arg²⁶Lys³⁹-GLP-1 (7-39); Gly⁸Arg³⁴Lys⁴⁰-GLP-1(7-40); Gly⁸Arg²⁶'³ Lys^36,40-GLP-1(7-40). Each one of these specific GLP-1 analogues constitutes an alternative embodiment of the invention.

In a further embodiment of the invention the GLP-1 analogue has the formula IV

A - GLP-1 (19-B) - X (IV)

wherein

A is a peptide comprising the amino acid residues of GLP-1 (8-18) or a fragment thereof; B is an integer in the range of 35-45; and

X is -OH, -NH₂, or a C^ alkyl amide or Ci-e dialkyl amide group; or an analogue thereof.

In an embodiment of the GLP-1 analogue of formula IV, A is a peptide selected from the group consisting of GLP-1 (8-18), GLP-1 (9-18), GLP-1 (10-18), GLP-1 (11-18), GLP-1 (12-18), GLP-1(13-18), GLP-1(14-18), GLP-1(15-18), GLP-1(16-18), GLP-1(17-18) and GLP-1 (18).

Preferably, A is GLP-1 (8-18), GLP-1 (9-18), GLP-1 (10-18), GLP-1 (11-18) or GLP-1 (12-18), and

B is 36, 37 or 38. Most preferably, A is GLP-1 (8-18).

In a further embodiment of the GLP-1 analogue of formula IV, B is 35, 36, 37, 38, 39,

40, 41 , 42, 43 or 44. In a more preferred embodiment, B is 36. In another more preferred embodiment. B is 37. In another more preferred embodiment, B is 38.

Such GLP-1 analogues of formula IV includes, but is not limited to

Arg²⁶-GLP-1(8-37);

Lys³⁶-GLP- 1(8-37);

Arg ⁶³ Lys³⁶-GLP-1 (8-37); Arg^{26 ;34}Lys³⁸GLP-1 (8-38);

Arg²⁶³ Lys³⁹-GLP-1 (8-39); Arg∞^Lys^-GLP-l (8-40); Arg²⁶Lys³⁶-GLP-1 (8-37); Arg^Lys -GLP-l (8-37);

Arg²⁶Lys³⁹-GLP-1 (8-39); Arg^Lys^-GLP-l (8-40);

Arg^{2o 34}Lys³⁶³⁹-GLP-1 (8-39); Arg²⁶'³ Lys³⁶⁴⁰-GLP-1 (8-40);

Gly⁸Arg²⁶-GLP-1 (8-37); Gly'Αrg^-GLP-l (8-37);

Gly⁸Lys³⁶-GLP-1 (8-37); Gly⁸Arg²⁶'³⁴Lys³⁶-GLP-1 (8-37);

Gly⁸Arg²⁶Lys³⁶-GLP-1 (8-37); Gly'Αrg^Lys -GLP-l (8-37);

Gly⁸Arg²⁶Lys³⁹-GLP-1 (8-39); Gly'Αrg^Lys^-GLP-l (8-40);

Gly'Αrg^Lys^-GLP-l (8-39); or

Gly⁸Arg²⁶'³ Lys³⁶'⁴⁰-GLP-1(8-40). Each one of these specific GLP-1 analogues constitutes an alternative embodiment of the invention.

In a further embodiment of the invention the GLP-1 analogue is Arg²⁶GLP-1(7-37). In a further embodiment of the invention the GLP-1 analogue is Arg³⁴GLP-1 (7-37).

In a further embodiment of the invention the salt is present in a concentration of at least 25 mM. In a further embodiment of the invention the salt is present in a concentration of from 25 mM to 800 mM, such as 100 to 200 mM. The salt may be added to the aqueous solution com- prising the GLP-1 analogue all at once or as a step or linear gradient.

In a further embodiment of the invention the salt is selected from inorganic salts. Such inorganic salts, includes but is not limited to chlorides, bromides, fluorides, iodides, sulphates or nitrates with ammonium, alkaline metals or earth alkaline metals, or mixtures thereof, e.g. NaCl, KCI, NH CI, CaCI₂, sodium sulphate, ammonium nitrate, potassium sulphate, ammo- nium sulphate, or mixtures thereof.

In a further embodiment of the invention the salt is selected from organic salts. Such organic salts, includes but is not limited to acetates, citrates or tartrates with ammonium, alkaline metals or earth alkaline metals, or mixtures thereof, e.g. sodium acetate, potassium acetate, ammonium acetate, sodium citrate, potassium citrate, potassium tartrate, ammo- nium citrate, calcium acetate or mixtures thereof.

In a further embodiment of the invention the organic solvent is present in a concentration of at least 0.5 %(vol/vol). In a further embodiment of the invention the organic solvent is present in a concentration of from 0.5 to 50 %(vol/vol), such as 1 to 15 %(vol/vol). The organic solvent may be added to the aqueous solution comprising the GLP-1 analogue all at once or as a step or linear gradient.

In a further embodiment of the invention the organic solvent is selected from d-β- alkanol, C^-alkenol, C₁_₆-alkynol, urea, guanidine, C^-alkanoic acid, ketone, DMSO, C₂-₆- glycol, C₃_ -polyalcohol including sugars, or mixtures thereof. Each of these solvents constitutes an individual embodiment of the invention. In a further embodiment of the invention the organic solvent is selected from C^- alkanol, ketone or C₃. -polyalcohol including sugars.

In a further embodiment of the invention the organic solvent is selected from metha- nol, ethanol, n-propanol, allyl alcohol, n-butanol, n-pentanol, n-hexanol, 2-propanol, tert-butyl alcohol, 1 ,2-ethanediol, 1 ,2-propanedipl, 2-methyl-2,4-pentanediol, glycerol, methylethyl ketone or acetone. Each of these solvents constitutes an individual embodiment of the invention. The organic solvent is preferably selected from ethanol, glycerol or acetone.

After preparation of the solution comprising a GLP-1 analogue, it is normally placed at ambient temperature, and the crystals will start to form after a while. After formation the crystals are isolated from the mother liquor. The temperature of the solution is easily decided by the skilled practitioner using his common general knowledge, and he may decide to place the solution at a constant temperature, or optionally place the solution at one temperature and then by step or linear gradient move the temperatur to a lower temperature.

In a further embodiment of the invention the solution is placed at a temperature from about -10°C to +40°C. In further embodiments of the invention the solution is placed at a tem- perature from -5°C to 40°C, -2°C to 40°C, -1 °C to 40°C, 4°C to 37°C, or 20 to 25°C. Each of these ranges constitutes an individual embodiment of the invention.

Formation of the crystals may start after 10-60 minutes although it may take a shorther or longer period of time. After formation of the crystals they may be isolated from the mother liquor by filtration, decantation, centrifugation or other means known to the skilled practitioner.

The present invention also relates to crystals, preferably needle shaped crystals, of a GLP-1 analogue optainable by the process comprising: a) preparing an aqueous solution comprising a GLP-1 analogue, a salt, and an organic solvent, and b) isolation of the crystals after formation.

The present invention also relates to needle shaped crystals of a GLP-1 analogue having a length of at least 0.5μm. In another embodiment of the invention the crystals are needle shaped crystals of a GLP-1 analogue having a length of at least 2μm. In a further embodiment of the invention the crystals are needle shaped crystals of a GLP-1 analogue having a length of 0.5μm to 50μm, such as 2μm to 50μm, e.g. 2μm to 30μm. In a further embodiment of the invention the crystals are needle shaped crystals of a GLP-1 analogue having a length of at least 8μm. In a further embodiment of the invention the crystals are needle shaped crystals of a GLP-1 analogue having a length of 8μm to 50μm.

In a further aspect the present invention relates to a pharmaceutical composition comprising crystals, preferably needle shaped crystals, of a GLP-1 analogue together with a pharmaceutically acceptable carrier or excipient.

The GLP-1 analogues can be produced by a method which comprises culturing or fermenting a host cell containing a DNA sequence encoding the GLP-1 analogue and capable of expressing said analogue in a suitable nutrient medium under conditions permitting the expression of the peptide, after which the resulting GLP-1 analogue is recovered from the culture or fermentation broth. Hereinafter, culturing will be used to cover both culturing and fermenting and the like.

The medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection). The GLP-1 analogue produced by the cells may then be recovered from the culture medium by conventional procedures including, optionally lysis of cells, separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by conventional purification techniques, such as chromatographic techniques, if necessary, purification by ion exchange chromatography according to the present invention, and subsequently, subjecting to analytical tests, e.g. PAGE, IEF, if necessary, subjecting to further purification, if necessary, and isolation of the pure GLP-1 analogue. The DNA sequence encoding the GLP-1 analogue may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the GLP-1 analogue by hybridisation using synthetic oligonucleotide probes in accordance with standard techniques (see, for example, Sambrook, J, Fritsch, EF and Maniatis, T, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1989). The DNA sequence encoding the GLP-1 analogue may also be prepared synthetically by established standard methods, e.g. the phosphoamidite method described by Beaucage and Caruthers, Tetrahedron Letters 22 (1981), 1859 - 1869, or the method described by Matthes et al., EMBO Journal 3 (1984), 801 - 805. The DNA sequence may also be prepared by polymerase chain reaction using specific primers, for instance as described in US 4,683,202 or Saiki et al., Science 239 (1988), 487 - 491.

The DNA sequence may be inserted into any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

The vector is preferably an expression vector in which the DNA sequence encoding the GLP-1 analogue is operably linked to additional segments required for transcription of the DNA, such as a promoter. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA encoding the GLP-1 analogue in a variety of host cells are well known in the art, cf. for instance Sambrook et al., supra. The DNA sequence encoding the GLP-1 analogue may also, if necessary, be operably connected to a suitable terminator, polyadenylation signals, transcriptional enhancer sequences, and translational enhancer sequences. The recombinant vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.

The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell or one which confers resistance to a drug, e.g. ampicillin, kanamycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.

To direct a GLP-1 analogue into the secretory pathway of the host cells, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector. The secretory signal sequence is joined to the DNA sequence encoding the GLP-1 analogue in the correct reading frame. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the GLP-1 analogue. The secretory signal sequence may be that normally associated with the GLP-1 analogue or may be from a gene encoding another secreted protein.

The procedures used to ligate the DNA sequences coding for the GLP-1 analogue, the promoter and optionally the terminator and/or secretory signal sequence, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., supra).

The host cell into which the DNA sequence or the recombinant vector is introduced may be any cell which is capable of producing the GLP-1 analogue and includes bacteria, vira, e.g. baculo virus, yeast, fungi, insect cells and higher eukaryotic cells. Examples of suitable host cells well known and used in the art are, without limitation, E. coli, Saccharomyces cerevisiae, or mammalian BHK or CHO cell lines.

Some of the GLP-1 analogue, can be produced according to conventional organic peptide synthetic chemistry. The resulting synthetic mixture may then be chemically modified, e.g. by alkylation, acylation, ester formation or amide formation or the like, and purified, or purified as it is and then modified chemically.

Usually, the fermentation broth comprising the GLP-1 analogue will also contain amino acids, small peptides, large peptides, unrelated proteins, reactants, cell debris, host cell proteins, endotoxins, and/or vira depending on whether recombinant DNA techniques and/or chemical modification techniques have been used or whether organic peptide synthetic chemis- try techniques have been used.

Thus, any method, such as an industrial method, for producing a GLP-1 analogue, which includes a crystallization step according to the present invention is also an aspect of the present application.

Accordingly, the present invention relates in a further aspect to a method for produc- ing a GLP-1 analogue or a GLP-1 analogue whereto is attached a lipophilic substituent comprising: a) expressing the GLP-1 analogue in a host cell, such as yeast, b) precipitating the analogue at its pi, c) preparing an aqueous solution comprising the GLP-1 analogue, a salt, and an organic solvent, and d) isolation of the crystals after formation, and e) further purification, optionally followed by repetition of steps b to e, to isolation of crystals of the GLP-1 analogue, and f) optionally acylation of the GLP-1 analogue, optionally followed by purification.

In a further aspect the present invention relates to a process for producing crystals of a GLP-1 analogue comprising: a) preparing an aqueous solution comprising a GLP-1 analogue, and a salt, and b) isolation of the crystals after formation.

Another invention relates to a process for producing crystals of a GLP-1 analogue comprising: a) preparing an aqueous solution comprising a GLP-1 analogue, and a salt, and b) isolation of the crystals after formation. Anyone of the above embodiments is also intended to represent embodiments of this invention where possible.

The term "an organic solvent", as used herein, is intended to include any organic solvent which do not denature the GLP-1 analogue. The organic solvent includes but is not limited to d-β-alkanol, d-6-alkenol or Ci-e-alkynol, urea, guanidine, or d-β-alkanoic acid, such as acetic acid, ketone, such as acetone, dimethylsulphoxide (DMSO), polymeric solvents, C₂-s- glycol, C₃. -polyalcohol including sugars, or mixtures thereof.

The term "d-β-alkanol", "d-e-alkenol" or "Ci-e-alkynol", as used herein, alone or in combination is intended to include those d-β-alkane, d-s-alkene or d-e-alkyne groups of the designated length in either a linear or branched or cyclic configuration whereto is linked a hydroxyl (-OH) (cf. Morrison & Boyd, Organic Chemistry, 4^th ed). Examples of linear alcohols are methanol, ethanol, n-propanol, allyl alcohol, n-butanol, n-pentanol and n-hexanol. Examples of branched alcohols are 2-propanoI and tert-butyl alcohol. Examples of cyclic alcohols are cyclo propyl alcohol and 2-cyclohexen-1-ol. The term "d-e-alkanoic acid", as used herein, is intended to include a group of the formula

R'COOH wherein R' is H or d-₅alkyl, such as acetic, propionic, butyric, α-methylbutyric, or valeric acid (cf. Morrison & Boyd, Organic Chemistry, 4^th ed).

The term "Cι-₁₂-alkyl", as used herein, is intended to include a branched or straight alkyl group having from one to 12 carbon atoms. Typical d-ι₂-alkyl groups are Cι_₅-alkyl groups which include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec- butyl, tert-butyl, pentyl, iso-pentyl, and the like (cf. Morrison & Boyd, Organic Chemistry, 4^th ed).

The term "d-β-glycol", as used herein, is intended to include a d-β-alkane containing two hydroxyl groups on different carbon atoms which may be adjacent or not. A typical C₂.₆-glycol include, but is not limited to 1 ,2-ethanediol, 1 ,2-propanediol, or 2-methyl-2,4-pentanediol (cf. Morrison & Boyd, Organic Chemistry, 4^th ed).

The term "C₂-₆-alkane", as used herein, is intended to include a branched or straight alkane group having from two to six carbon atoms. Typical d-β-alkane groups include, but are not limited to ethane, propane, iso-propane, butane, iso-butane, pentane, hexane and the like (cf. Morrison & Boyd, Organic Chemistry, 4^th ed).

The term "C₃.₇-polyalcohol including sugars", as used herein, is intended to include a group of the formula HOCH₂(CHOH)_nCH₂OH wherein n is an integer from 1-5, and monosaccharides such as glycerol, mannose, glucose (cf. Morrison & Boyd, Organic Chemistry, 4^th ed). The term "a GLP-1 analogue", as used herein, is intended to designate GLP-1 (7-37),

GLP-1 (7-36) amide as well as analogues, fragments, homologues, and derivatives thereof, which are capable of being produced by conventional recombinant DNA techniques as well as conventional synthetic methods. Such GLP-1 analogues include but are not limited to native glucagon-like peptide-1 , for instance such peptide fragments which comprises GLP-1 (7-37) and functional derivatives thereof as disclosed in WO 87/06941 ; such peptide fragments which comprise GLP-1 (7-36) and functional derivatives thereof as disclosed in WO 90/11296; such analogues of the active GLP-1 peptides 7-34, 7-35, 7-36, and 7-37 as disclosed in WO 91/11457; such N-terminal truncated fragments of GLP-1 as disclosed in EP 0699686-A2; such GLP-1 analogues and derivatives that include an N-terminal imidazole group as disclosed in EP 0708179-A2; and such exendins as disclosed in WO 9746584 and US 5424286.

The term "exendins", as used herein, is intended to designate exendin as well as analogs, derivatives, and fragments thereof, e.g. exendin-3 and -4. Examples of exendin as well as analogs, derivatives, and fragments thereof to be included within the present invention are those disclosed in WO 9746584 and US 5424286. US 5424286 describes a method for stimulating insulin release with exendin polypeptide(s). The exendin polypeptides disclosed include HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGX; wherein X = P or Y, and HX1X2GTFITSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS; wherein X1X2 = SD (exendin- 3) or GE (exendin-4)). The exendin-3 and -4 and fragments are useful in treatment of diabetes mellitus (types I or II) and prevention of hyperglycaemia. They normalise hyperglycaemia through glucose-dependent, insulin-independent and insulin-dependent mechanisms. Exendin- 4 is specific for exendin receptors, i.e. it does not interact with vasoactive intestinal peptide re- ceptors. WO 9746584 describes truncated versions of exendin peptide(s) for treating diabetes. The disclosed peptides increase secretion and biosynthesis of insulin, but reduce those of glu- cagon. The truncated peptides can be made more economically than full length versions.

The term "crystals" as used herein, is intended to designate crystals of any shape, such as single needle shaped crystals (which is the same as needle-like crystals), single irregular shaped crystals, single oblong crystals as well as clusters of two or more crystals and mixtures thereof (cf. "Preparation and analysis of protein crystals" by A. McPherson).

The term "non-synthetic GLP-1 analogues" as used herein, is intended to designate a GLP-1 analogue which comprises only naturally occurring amino acid residues and is capable of being produced by recombinant DNA techniques or expressed by organisms, e.g. microorganisms.

The term "ketone" as used herein, is intended to designate a compound of the formula R¹-CO-R² wherein R¹ and R² are independently of each other selected from d-₁₂-alkyl, preferably d-₅-alkyl (cf. Morrison & Boyd, Organic Chemistry, 4^th ed). The term "polymeric solvents" as used herein, is intended to comprise poly(acrylic acid), carboxymethylcellulose, poly(ethylene glycol), poly(propylene glycol), poly(vinyl alcohol), poly(vinylpyrrolidone) and the like (cf. "Preparation and analysis of protein crystals" by A. McPherson).

The term "analogues" as used herein, is intended to designate a peptide wherein one or more amino acid residues of the parent peptide have been substituted by another amino acid residue and/or wherein one or more amino acid residues of the parent peptide have been deleted and/or wherein one or more amino acid residues have been added to the parent peptide. Such addition can take place either at the N-terminal end or at the C-terminal end of the parent peptide or both. The term "derivatives" as used herein, is intended to designate a peptide in which one or more of the amino acid residues of the parent peptide have been chemically modified, e.g. by alkylation, acylation, ester formation or amide formation or the like.

The term "a salt" as used herein, is intended to include any organic or inorganic salt, including but not limited to NaCl, KCI, NH CI, CaCI₂, sodium acetate, potassium acetate, ammonium acetate, sodium citrate, potassium citrate, ammonium citrate, sodium sulphate, potassium sulphate, ammonium sulphate, calcium acetate or mixtures thereof (cf. Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, or Remington: The Science and Practice of Pharmacy, 19th Edition (1995), or handbooks from Amer- sham-Pharmacia Biotech). The term "a buffer" as used herein, is intended to include any buffer including but not limited to: citrate buffers, phosphate buffers, tris buffers, bis-Tris buffer, borate buffers, lac- tate buffers, glycyl glycin buffers, arginine buffers, carbonate buffers, acetate buffers, gluta- mate buffers, ammonium buffers, glycin buffers, alkylamine buffers, aminoethyl alcohol buffers, ethylenediamine buffers, tri-ethanol amine, imidazole buffers, pyridine buffers and barbiturate buffers and mixtures thereof (cf. Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, or Remington: The Science and Practice of Pharmacy, 19th Edition (1995), or handbooks from Amersham-Pharmacia Biotech).

The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection. The features disclosed in the foregoing description and in the following examples may, both separately and in any combination thereof, be material for realising the invention in diverse forms thereof.

Experimental part

Crystallisation of Arg³⁴GLP1₍₇.₃₇₎ in the Manufacturing Process for preparing a mono acylated GLP-1 analogue

Arg³⁴GLP1₍₇.₃₇₎ was expressed in yeast, that is Saccharomyces cerevisiae (Sacch. cerevisiae), by conventional recombinant DNA technology. The fermentation broth was purified by a conventional reverse phase capture step followed by a first precipitation step (precipitate (A)) at the iso-electric point (pi) of Arg³⁴GLP1₍₇.₃₇₎. Arg³⁴GLP1₍₇.₃₇₎ was then re- dissolved and further purified by conventional High Performance Cation Exchange Chromatography (HP-CIEC) and Reverse Phase High Performance Liquid Chromatography (RP- HPLC) followed by a second precipitation step (precipitate (B)) at the pi of Arg³⁴GLP1₍₇.₃₇₎. Then Arg³⁴GLP1₍₇.₃₇₎was acylated, e.g. as disclosed in WO 98/08871 , and the resulting solution containing mono-acylated Arg³⁴GLP1₍₇.₃₇₎ was further purified by conventional RP-HPLC and finally precipitated at pi of mono-acylated Arg^GLPI^^.

The implementation of a crystallisation step in the manufacturing process for the preparation of mono-acylated Arg³ GLP1₍₇-₃₇₎ results in removal of coloured compounds from the fermentation broth, reduction of Saccharomyces cerevisiae proteins (host cell proteins) (SCP) as well as removal of water, and low loss of Arg³⁴GLP1₍₇.₃₇₎ from the mother liquor. Crystallisation of Arg³⁴GLP1₍₇-₃₇₎ from precipitate (A) and precipitate (B) has been performed. An overview of the experiments is given in the following section along with a description of the crystallisation procedure. General procedure:

The precipitate (A) from the first precipitation step (or the precipitate (B) from the second precipitation step) was suspended in water and pH was adjusted to pH 8.5-9.5 with NaOH by which the precipitate dissolved. The Arg³⁴GLP1₍₇.₃₇₎ concentration (referred to as GLP1 cone. in the tables) of the stock solution was measured by analytical RP-HPLC (Analytical procedure 427-AF006.D02: Purity and Concentration of GLP-1 (Inger Bastholm, 1999)). Then salt, organic solvent and buffer compound was added to the desired concentration and the solution was adjusted to the specified pH with HCI, then gently swirled and placed at the specified temperature (scale: 3-5 ml). Formation of crystals started to occur after 10-60 minutes and after 16-18 hr the crystal morphology was studied in microscope (Microscope BX50 from Olympus). For quantification a portion of the mother liquor was removed and centrifuged. The Arg³⁴GLP1₍₇-₃₇₎ content was measured by analytical RP-HPLC. The loss by crystallisation was calculated by division of the supernatant content by the content in the starting material.

N.A. = Not Assessed

r f

Claims

1. A process for producing crystals of a GLP-1 analogue comprising: a) preparing an aqueous solution comprising a GLP-1 analogue, a salt, and an organic solvent, and b) isolation of the crystals after formation.

2. The process according to claim 1 wherein in step a) adjusting pH to pl-4<pH<pl, or to pl<pH<pl+4, wherein pi is the isoelectric point of the GLP-1 analogue.

3. The process according to any one of claims 1-2 wherein the crystals are needle shaped crystals of a GLP-1 analogue.

4. The process according to any one of claims 1-3 wherein the crystals has a length of at least 0.5μm.

5. The process according to any one of claims 1-4 wherein the GLP-1 analogue in the aque- ous solution has a purity of less than 95%, as measured by HPLC.

6. The process according to any one of claims 1-5 wherein the GLP-1 analogue in the aqueous solution is present in a concentration of at least 0.5 mg/ml.

7. The process according to any one of claims 1-6 wherein the GLP-1 analogue is selected from non-synthetic GLP-1 analogues.

8. The process according to any one of claims 1-7 wherein the GLP-1 analogue is Arg³ GLP- 1 (7-37) or Arg²⁶GLP-1 (7-37).

9. The process according to any one of claims 1-8 wherein the salt is present in a concentration of at least 25 mM.

10. The process according to any one of claims 1-9 wherein the organic solvent is present in a concentration of from 0.5 to 50 %(vol/vol).

11. The process according to any one of claims 1-10 wherein the organic solvent is selected from d-β-alkanol, d-β-alkenol, d-β-alkynol, urea, guanidine, Ci-β-alkanoic acid, ketone, DMSO, d-₆-glycol, C₃_₇-polyalcohol including sugars, or mixtures thereof.

12. A method for producing a GLP-1 analogue or a GLP-1 analogue whereto is attached a lipophilic substituent comprising the steps: a) preparing an aqueous solution comprising a GLP-1 analogue, a salt, and an organic solvent, and b) isolation of the crystals after formation.

13. Crystals of a GLP-1 analogue optainable by the process comprising: a) preparing an aqueous solution comprising a GLP-1 analogue, a salt, and an organic solvent, and b) isolation of the crystals after formation.

14. Needle shaped crystals of a GLP-1 analogue.

15. A pharmaceutical composition comprising needle shaped crystals of a GLP-1 analogue and a pharmaceutically acceptable carrier.